GlassScriptPhysician profile
Michael L Shomaker
NPI 1932276581
$40,828.34
in general payments reported to CMS, 2019-2025
20 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $95.51 · 2021: $13.60 · 2022: $59.76 · 2023: $290 · 2024: $20K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $1,789 · Travel and Lodging: $921 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,620.00 |
| Food and Beverage | $1,788.55 |
| Travel and Lodging | $920.97 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37,017.03 | 2024-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $2,061.96 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $385.89 | 2022-2025 | Farxiga, Lokelma, Evusheld |
| Nxstage Medical, INC. | $220.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $206.74 | 2020-2025 | Jynarque |
| Glaxosmithkline, LLC. | $205.68 | 2023-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $131.58 | 2024-2025 | |
| Amgen INC. | $126.92 | 2024-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $93.30 | 2024-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $60.63 | 2023-2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $58.44 | 2023-2024 | Tarpeyo |
| Novo Nordisk INC | $47.79 | 2024-2025 | Ozempic, Rivfloza |
| Vifor Pharma, INC. | $45.66 | 2019 | |
| Horizon Therapeutics Plc | $39.52 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $27.90 | 2025 | Ultomiris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.23 | 2019 | |
| Amicus Therapeutics, INC. | $23.10 | 2019 | |
| Chiesi USA, INC. | $21.41 | 2025 | Elfabrio |
| Travere Therapeutics, INC. | $16.89 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shomaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.